Search / Trial NCT06614179

A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established

Launched by XIANGDONG CHENG · Sep 25, 2024

Apply for Trial

Trial Information

Current as of December 22, 2024

Recruiting

Keywords

ClinConnect Summary

This clinical trial is focused on developing a new way to screen and diagnose abdominal tumors using CT scans. The goal is to create a model that can help identify these tumors more effectively, which could lead to earlier treatment and better outcomes for patients. The study is currently recruiting participants, and it is open to individuals aged between 65 and 74 years old, regardless of gender, who have been diagnosed with abdominal tumors or are part of a non-tumor population.

To be eligible for the trial, participants with tumors must have a confirmed diagnosis and complete medical records, including follow-up information about their health over the past two years. They should not have had any major abdominal issues or infections in the three months leading up to the study. Participants without tumors must also have clear medical records and no history of serious abdominal diseases or cancers. During the trial, participants can expect to undergo CT scans, which are quick and painless, and their data will contribute to improving the understanding of abdominal tumors.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Patients with abdominal tumors:
  • • all patients were pathologically diagnosed with abdominal tumors;
  • • The clinical case data of all patients were complete, and complete follow-up was obtained, with clear information on medical visits, operation time and survival status within 2 years. If the cause of death is unknown, it will be recorded as censored data;
  • • All patients had no history of active abdominal bleeding, no serious infection or other abdominal diseases that affected the observation of CT imaging within 3 months before surgery.
  • * Non-tumor population:
  • • all patients have complete clinical case data, complete abdominal CT, no history of malignant tumors, no serious infections or other abdominal diseases that affect the diagnosis and observation of CT imaging.
  • Exclusion Criteria:
  • • Cases in which contrast-enhanced or noncontrast CT images show unclear lesions, with significant noise and artifacts;

Trial Officials

Xiangdong Cheng

Principal Investigator

Zhejiang Cancer Hospital

About Xiangdong Cheng

Xiangdong Cheng is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapeutic approaches, the organization collaborates with leading institutions and regulatory bodies to ensure rigorous trial design, patient safety, and data integrity. By leveraging a multidisciplinary team of experts, Xiangdong Cheng aims to facilitate the efficient progression of clinical studies, ultimately enhancing treatment options and improving patient outcomes in various therapeutic areas. Their commitment to excellence and ethical standards underscores their role as a pivotal player in the clinical research landscape.

Locations

Hangzhou, Zhejiang, China

Hangzhou, Zhejiang, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0